MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Aspira Women's Health Gross Profit 2011-2026 | AWH
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Aspira Women's Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.32 M | 3.06 M | 1.24 M | 1.2 M | -89 K | 207 K | -56 K | -132 K | 1.29 M | 2.4 M | 1.96 M | 1.79 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.32 M | -132 K | 1.43 M |
Quarterly Gross Profit Aspira Women's Health
| 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.38 M | 1.56 M | - | 1.36 M | 1.42 M | 1.21 M | - | 1.31 M | 1.55 M | 1.19 M | - | 1.16 M | 966 K | 961 K | - | 749 K | 696 K | 603 K | - | 432 K | 153 K | 420 K | - | 336 K | 234 K | 109 K | - | -4 K | -100 K | -154 K | - | -80 K | 204 K | -1 K | - | -194 K | 122 K | -23 K | - | -427 K | -39 K | 460 K | - | -283 K | 236 K | 250 K | - | 305 K | 289 K | 291 K | - | 286 K | 293 K | 274 K | - | 294 K | 267 K | 389 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.56 M | -427 K | 465 K |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
83.8 K | $ 3.03 | -2.26 % | $ 98.3 K |  USA |
 |
Trinity Biotech plc
TRIB
|
21.4 M | $ 0.83 | -5.96 % | $ 61.9 M |  Irlanda |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
30.6 M | $ 23.35 | -2.91 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
364 M | $ 34.5 | 2.16 % | $ 371 M |  China |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
2.77 M | $ 1.29 | -12.26 % | $ 1.64 M | USA |
 |
Castle Biosciences
CSTL
|
53 M | $ 39.74 | 1.48 % | $ 1.1 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
2.63 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
14.2 B | $ 219.29 | -0.08 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
493 M | $ 102.41 | 0.1 % | $ 19 B | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 26.19 | -0.19 % | $ 792 M | USA |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
144 M | $ 113.17 | 2.43 % | $ 13.9 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
2.29 B | $ 73.31 | -0.93 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 20.55 | -1.23 % | $ 1.1 B | USA |
 |
DarioHealth Corp.
DRIO
|
5.98 M | $ 10.2 | -0.97 % | $ 289 M | Israel |
 |
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
988 M | $ 66.91 | 0.34 % | $ 4.63 B | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
2.86 B | $ 144.81 | -3.26 % | $ 23 B | USA |
 |
NeoGenomics
NEO
|
290 M | $ 11.99 | -3.35 % | $ 1.52 B | USA |
 |
QIAGEN N.V.
QGEN
|
967 M | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
3.79 B | $ 230.33 | -2.19 % | $ 41.8 B | USA |
 |
Charles River Laboratories International
CRL
|
958 M | $ 210.51 | -0.59 % | $ 10.8 B | USA |
 |
Personalis
PSNL
|
22.1 M | $ 9.33 | -6.42 % | $ 553 M | USA |
 |
Medpace Holdings
MEDP
|
246 M | $ 582.66 | -1.76 % | $ 18 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 186.45 | 2.27 % | $ 20.7 B | USA |
|
Biodesix
BDSX
|
18.5 M | $ 10.11 | 4.66 % | $ 1.31 B | USA |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
6.02 M | $ 24.07 | -0.78 % | $ 31.2 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
3.62 B | $ 271.34 | 0.56 % | $ 22.8 B | USA |
 |
Mettler-Toledo International
MTD
|
2.33 B | $ 1 370.47 | -1.61 % | $ 29.1 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 181.44 | -2.39 % | $ 15 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
2.38 B | $ 672.84 | -0.57 % | $ 55.5 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
7.77 B | $ 28.66 | -2.02 % | $ 20 B | Niderland |
 |
Agilent Technologies
A
|
2.84 B | $ 133.33 | 0.07 % | $ 40.5 B | USA |